16:13 EDT Aravive files $250M mixed securities shelf
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARAV:
- Aravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)
- Aravive To Participate in the Jefferies Global Healthcare Conference
- Aravive Announces Phase 3 Trial Design for Batiraxcept in Clear Cell Renal Cell Carcinoma
- Aravive to Host Virtual KOL Event on its Late-Stage Oncology Asset Batiraxcept
- Is ARAV a Buy, Before Earnings?